Skip to main content
SpringerLink
Log in
Book cover

Integrin Targeting Systems for Tumor Diagnosis and Therapy pp 51–68Cite as

Preparation, Characterization, and In Vitro and In Vivo Evaluation of PEGylated Liposomal Doxorubicin Modified with Different cRGD Peptides

  • Protocol
  • First Online:

  • 461 Accesses

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

Liposomes containing cytotoxic agents and decorated with Cyclic Arg-Gly-Asp (cRGD) pentapeptides have attracted considerable attention for targeting tumor vasculature. These cRGD peptides have been used for targeting liposomes or other nano-carriers to inflamed or tumoral tissues; however, no comparative study dealing with the biological performances of liposomes decorated with different cRGDs could be found in the literature.

Herein, we prepared PEGylated Liposomal Doxorubicin (PLD) conjugated with different three cRGD peptides (RGD-PLDs). RADyC-PLD and not modified PLDs (Plain-PLD) were prepared as negative controls. Then, all the preparations were comparatively evaluated with respect to their in vitro behaviors (cell interactions and cytotoxicity) and in vivo performances (biodistribution and therapeutic efficacy) in tumored mice.

In this chapter, we present the general flowchart applied for this project as follow: (1) preparation of peptide-modified PLDs, (2) characterization of colloidal properties and stability of PLDs, (3) in vitro cell interaction and cytotoxicity, and (4) in vivo biodistribution and therapeutic efficacy in mice bearing C-26 colon carcinoma tumor model.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Gottschalk KE, Kessler H (2002) The structures of Integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed 41(20):3767–3774. doi:10.1002/1521-3773(20021018)41:20<3767::Aid-Anie3767>3.0.Co;2-T

    Article  CAS  Google Scholar 

  2. Chen K, Chen X (2011) Integrin targeted delivery of chemotherapeutics. Theranostics 1:189–200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ruoslahti E (2003) The RGD story: a personal account. Matrix Biol 22(6):459–465, S0945053X03000830 [pii]

    Article  CAS  PubMed  Google Scholar 

  4. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309(5963):30–33

    Article  CAS  PubMed  Google Scholar 

  5. Heckmann D, Meyer A, Marinelli L, Zahn G, Stragies R, Kessler H (2007) Probing integrin selectivity: rational design of highly active and selective ligands for the alpha 5 beta 1 and alpha v beta 3 integrin receptor. Angew Chem Int Ed 46(19):3571–3574. doi:10.1002/anie.200700008

    Article  CAS  Google Scholar 

  6. Temming K, Schiffelers RM, Molema G, Kok RJ (2005) RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8(6):381–402. doi:10.1016/j.drup.2005.10.002, S1368-7646(05)00087-7 [pii]

    Article  CAS  PubMed  Google Scholar 

  7. Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16(3):80–88. doi:10.1016/j.tcm.2006.01.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Salvati M, Cordero FM, Pisaneschi F, Melani F, Gratteri P, Cini N, Bottoncetti A, Brandi A (2008) Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands. Bioorg Med Chem 16(8):4262–4271. doi:10.1016/j.bmc.2008.02.080, S0968-0896(08)00201-0 [pii]

    Article  CAS  PubMed  Google Scholar 

  9. Cini N, Trabocchi A, Menchi G, Bottoncetti A, Raspanti S, Pupi A, Guarna A (2009) Morpholine-based RGD-cyclopentapeptides as alpha(v)beta(3)/alpha(v)beta(5) integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem 17(4):1542–1549. doi:10.1016/j.bmc.2009.01.006

    Article  CAS  PubMed  Google Scholar 

  10. Heckmann D, Kesster H (2007) Design and chemical synthesis of integrin ligands. Integrins 426:463. doi:10.1016/S0076-6879(07)26020-3

    Article  CAS  Google Scholar 

  11. Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10(10):753–768

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23(4):217–225

    Article  CAS  PubMed  Google Scholar 

  13. Barenholz Y (2012) Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134. doi:10.1016/j.jconrel.2012.03.020, S0168-3659(12)00230-1 [pii]

    Article  CAS  PubMed  Google Scholar 

  14. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q (2005) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107(2):262–275. doi:10.1016/j.jconrel.2005.03.030, S0168-3659(05)00121-5 [pii]

    Article  CAS  PubMed  Google Scholar 

  15. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q (2005) Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 94(8):1782–1793. doi:10.1002/jps.20397

    Article  CAS  PubMed  Google Scholar 

  16. Schiffelers RM, Koning GA, ten Hagen TLM, Fens MHAM, Schraa AJ, Janssen ANPCA, Kok RJ, Molema G, Storm G (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91(1-2):115–122. doi:10.1016/S0168-3659(03)00240-2

    Article  CAS  PubMed  Google Scholar 

  17. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31(1):11–19, doi:S0969805103001288 [pii]

    Article  CAS  PubMed  Google Scholar 

  18. Hersel U, Dahmen C, Kessler H (2003) RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 24(24):4385–4415, doi:S0142961203003430 [pii]

    Article  CAS  PubMed  Google Scholar 

  19. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M (2005) Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293(1-2):281–290. doi:10.1016/j.ijpharm.2004.12.021, S0378-5173(05)00056-6 [pii]

    Article  CAS  PubMed  Google Scholar 

  20. Amin M, Badiee A, Jaafari MR (2013) Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm 458:324. doi:10.1016/j.ijpharm.2013.10.018

    Article  CAS  PubMed  Google Scholar 

  21. Zuidam NJ, Vrueh RD, Ceommelin DJA (2003) Characterization of liposomes. In: Torchilin VO, Weissig V (eds) Liposomes a practical approach, 2nd edn, Practical approach. Oxford University Press, New York, NY, pp 32–33

    Google Scholar 

  22. Horowitz AT, Barenholz Y, Gabizon AA (1992) In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1109(2):203–209, 0005-2736(92)90084-Y [pii]

    Article  CAS  PubMed  Google Scholar 

  23. Huang Z, Szoka FC Jr (2008) Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc 130(46):15702–15712. doi:10.1021/ja8065557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Huang Z, Jaafari MR, Szoka FC Jr (2009) Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem Int Ed Engl 48(23):4146–4149. doi:10.1002/anie.200900111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12(5):1606–1614. doi:10.1158/1078-0432.CCR-05-1566, 12/5/1606 [pii]

    Article  CAS  PubMed  Google Scholar 

  26. Hermanson GT (2008) The chemistry of reactive groups, 2nd edn, Bioconjugate techniques. Elsevier, Houston, TX, pp 169–221

    Google Scholar 

  27. Vacha J (1975) Blood volume in inbred strain BALB/c, CBA/J and C57BL/10 mice determined by means of 59Fe-labelled red cells and 59Fe bound to transferrin. Physiol Bohemoslov 24(5):413–419

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biotechnology Research Center, Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, 91775-1365, Iran

    Mohamadreza Amin

  2. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, 91775-1365, Iran

    Mahmoud Reza Jaafari

Authors
  1. Mohamadreza Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmoud Reza Jaafari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmoud Reza Jaafari .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology and Hepatology, UniversitätsSpital Zürich, Zürich, Switzerland

    Eleonora Patsenker

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Amin, M., Jaafari, M.R. (2015). Preparation, Characterization, and In Vitro and In Vivo Evaluation of PEGylated Liposomal Doxorubicin Modified with Different cRGD Peptides. In: Patsenker, E. (eds) Integrin Targeting Systems for Tumor Diagnosis and Therapy. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/7653_2015_57

Download citation

  • DOI: https://doi.org/10.1007/7653_2015_57

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7443-6

  • Online ISBN: 978-1-4939-7445-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation